The Best Healthcare Stocks to Buy With $50 Right Now

Pfizer is trading near $27 at ~9x forward P/E versus the healthcare average of 17.8, Novo Nordisk around $39 at a ~10.4x forward P/E, and Exelixis about $41. Key catalysts: Pfizer's deep oncology and chronic weight-management pipeline and reduced COVID-product reliance could materially boost sales/profits over the next 5 years; Novo Nordisk remains well-positioned in the expanding weight-loss market with Wegovy/oral candidates and additional pipeline assets; Exelixis benefits from Cabometyx revenue and promising CRC data for zanzalintinib but faces a Cabometyx patent cliff in early 2030. Given current valuations, the article views these names as attractively priced with upside from pipeline/regulatory wins, but timing and execution risk remain.

Analysis

Winners are likely to be companies that control manufacturing scale, payer relationships, and combination-label optionality rather than pure single-drug exposure — that structurally favors incumbents that can re-deploy capacity and cross-sell into chronic care. Second-order beneficiaries include CDMOs and large oncology partners that supply combo therapies and companion diagnostics, and conversely, pure-play small-cap competitors without commercial infrastructure are at risk if payers centralize access.

Key catalysts cluster by horizon: clinical readouts and label expansions (6–24 months) will drive binary re-ratings for Exelixis and parts of Pfizer’s oncology line; payer negotiations and real-world adherence data (12–36 months) will determine durable pricing for GLP-1/OAM segments where Novo Nordisk competes. Tail risks include aggressive payer step therapy, emergent safety signals for GLP-1/combination regimens, and a concentrated patent cliff dynamic that forces hurried M&A or royalty monetization decisions by 2028–2031.

From a positioning standpoint, asymmetric payoff exists in owning differentiated franchises that can monetize label expansion while hedging commoditization risk: Exelixis’ combo pipeline is event-driven upside with limited downside to current cash flows, Novo Nordisk’s growth is hit-or-miss on access and pricing, and Pfizer’s optionality is in platform redeployment and M&A execution after COVID revenue normalization. Monitor near-term CDS flows and large-block insider/partner transactions as high-signal indicators of conviction ahead of readouts.

The consensus underestimates how quickly payers can blunt headline volume growth by shifting formularies and instituting prior-authorizations — that will compress gross-to-net more than models currently assume and favor firms with diversified margin drivers. Conversely, the market also underprices targeted oncology label wins that can re-rate smaller biotechs via durable royalties and partnership economics; those are the asymmetric opportunities to harvest with event-based sizing.

Key Decisions for Investors

• Long NVO (12–36 months): buy a core position sized for 30–40% upside to a base-case market-share rebound; finance with the sale of 9–12 month covered calls to trim cost. Hedge: purchase 18–24 month OTM puts ~10% below cost to cap tail risk from accelerated payer restrictions. R/R: pay ~1–2% of notional for insurance to preserve ~3:1 upside/downside asymmetry under base-case approvals and access wins.
• Long EXEL (6–24 months, event-driven): accumulate ahead of upcoming registrational readouts—size as a tactical allocation (5–8% biotech sleeve) and fund via selling 6–9 month OTM calls to reduce basis. Risk: a failed combo readout would likely reprice shares >30%; limit position to event-sized exposure and set stop-loss at 25% on non-confirmatory interim data.
• Tactical PFE trade (3–9 months): buy on pullbacks into structural support with a sell-call overlay (covered calls 3–6 months) to monetize low volatility while retaining upside to any surprise oncology wins or corporate activity. If looking for asymmetric exposure, use a calendar call spread (near-term sold, longer-term bought) to capture recovery in mid-term earnings without paying full long-premium.
• Pair idea for protection: long NVO / short a broader large-cap biotech basket (or synthetic short via options) for 12–24 months to isolate GLP-1 share-recovery vs. sector-wide pricing risk. This reduces idiosyncratic biotech drawdowns while keeping beta to payer-driven margin compression low.